The most prominent example is the combination of radiotherapy with cetuximab, an inhibitory antibody directed against the epidermal growth factor receptor (EGFR) which is used to treat patients with head and neck squamous cell carcinoma (HNSCC; [2]). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.